Articles On Immutep (ASX:IMM)

Highlights Market activity across the ASX revealed strong divergence among sectors. Defence technology, healthcare, and infrastructure companies led the advancing side. Mining, biotech, and investment firms featured among th...

Highlights Rising geopolitical tensions weigh on Australian equities Mining stocks face pressure while energy and defence firms gain attention Banking sector steadies market sentiment amid rate expectations Heightened...

Highlights Oil surge unsettles Australian sharemarket sentiment Mining giants face pressure from rising energy costs Banking stocks display steadier momentum Global energy developments have triggered fresh volatility a...

ASX slips 0.14% on Friday, but ends up 0.17% over the past five days Oil prices remain high, with Brent crude hovering around US$100/barrel Energy stocks rise alongside mining and banking majors   ASX stumbles to week’s end The S&P/AS...

Highlights Clinical study halt shakes confidence in biotech pipeline. Lung cancer program setback triggers sharp market reaction. Focus shifts toward remaining research programs. A halted late-stage lung cancer trial h...

ASX health sector falls about 2.5% for the past five days while broader market is just scraping by as the Middle East conflict takes a toll Immutep plunges 90% on Friday after abandoning its Phase III trial of lung cancer treatment  Pro Me...

Good Afternoon, I’m Jon Davidson, it’s a Friday and you know what that means – it’s time for HotCopper Highlights, the segment where we wrap up the stocks and company announcements you were watching and viewing the most this week on Austral...

Immutep Ltd (ASX:IMM) has seen its share price slaughtered on Friday after it’s effectively ditched its lead candidate for the treatment of lung cancer, a move that spells doom for any biotech – the speculative trader’s speculative investme...

It looks like it will be a day to forget for owners of Immutep Ltd (ASX: IMM) shares on Friday. In morning trade, the ASX biotech stock is down a massive 93% to 2.8 cents. Why is this ASX biotech stock having a day to forget? Investors have...

The Immutep Ltd (ASX: IMM) share price is currently halted on Monday. This comes after the biotech company requested a trading halt from the ASX late last week. Before being placed on ice, shares in the cancer immunotherapy develope...

Oil prices have surged as the war between the United States, Israel, and Iran intensifies across the Middle East. Brent crude and West Texas Intermediate (WTI) crude have both climbed above the US$100 per barrel mark for the first time...

Now could be the time to pounce on the ASX biotech stock in this article according to analysts at Bell Potter. That's because it believes the speculative stock could generate very big returns over the next 12 months if everything goes to pl...

ASX healthcare sector falls 13.31% in February as benchmark ASX 200 up 4% Blood products and vaccines giant CSL weighed heavily on sector down 19.1% in February Rhythm Biosciences up 48% in February to be sector’s biggest gainer for the mo...

Local life sciences players eyeing developing geographies for potentially higher returns Bioscience Managers talks Türkiye on $145 million fund Adalta’s ‘east meets west’ drug procurement strategy gains traction   As the world’s biggest h...

S&P/ASX 300 Index (ASX: XKO) healthcare share Immutep Ltd (ASX: IMM) is joining the broader market sell-down today. Shares in the clinical-stage biotech company closed yesterday trading for 38 cents. In morning trade on Friday, shares a...

ASX healthcare sector rises 2.25% in January as benchmark ASX 200 up 1.78% Index largely supported by the sector’s largest stock CSL, up 5.1% in January Anteris and PYC announce monster capital raises with strong support from US investors...

The Immutep Ltd (ASX: IMM) share price is in the red today after the company released its latest quarterly update. At the time of writing, the Immutep share price is down 2.95% to 42.7 cents. That short-term dip comes despite a solid...

With the sun setting on another ‘issues rich’ year for ASX biotechs, Dr Boreham applies his stethoscope to the soaring highlights and cratering lowlights.   As usual we adopt the user-friendly A to Z format. If only drug, device and diagnos...

The Brightstar Resources Ltd (ASX: BTR) share price is under pressure today after the company released an update this morning. At the time of writing, the emerging gold producer's shares are trading at 51 cents, down 9.73%. So,...

Immutep Ltd (ASX: IMM) has reported positive results from a clinical trial of a drug it is developing in a bid to treat autoimmune diseases in a novel fashion. The biotechnology company said in a statement to the ASX on Monday morning t...

A federal ‘advanced overseas finding’ means Recce can claim up to $85 million in R&D tax offsets Radiopharm is ‘grossly mispriced’, says Bell Potter Entropy Neurodynamics treats first patient in binge eating disorder trial   A develop...

Healthcare slides 1.3% for the week despite the wider market lifting 0.7% Immutep surges 46% on lucrative global licensing deal with Dr. Reddy’s PolyNovo wins Morgans upgrade as new leadership team takes charge   Healthcare and life scien...

The ASX lithium share Pilbara Minerals Ltd (ASX: PLS) has had an incredible performance in 2025 to date, rising by around 80%, as the below chart shows. You may be wondering what's predicted for the business in the coming year. PLS Gr...

Cogstate shares plunge on revenue and earnings downgrade Immuron shares have the runs after failed US military trial Was Immutep’s share price reaction underdone?   CogState (ASX:CGS) shares have tumbled as much as 30% on the back of a r...

If you have a high tolerance for risk, then it could be worth checking out the small cap ASX stock in this article. That's because Bell Potter believes the signing of an "impressive deal" could be the catalyst to sending its shares material...

The ASX 200 jumped 0.15% to a session high after the RBA held rates before plunging to -0.45% Bloodbath across sectors and indices, lower across the board Strong gains in some lithium and defence stocks despite bearish market ASX ducks a...

Pilbara Minerals shares have been one of the most prominent lithium stocks on the ASX for years now. The company first started attracting major attention in 2015, when it rose by about 900% at one point. In subsequent years, the gains conti...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has followed Wall Street's lead and dropped into the red. At the time of writing, the benchmark index is down 0.2% to 8,609.6 points. Four ASX shares that are not letting that hold t...

Immutep has struck a global deal to commercialise its novel immuno-oncology asset Broker Morgans values Epiminder shares at $2.33 – almost twice their current value Rhythm gets into the US groove with genetic test deal   Shares in immuno-...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

The S&P/ASX 300 Index (ASX: XKO) is down 0.3% today despite the best efforts of this rocketing ASX 300 healthcare share. The surging stock in question is clinical-stage biotech company Immutep Ltd (ASX: IMM). Immutep shares closed yeste...

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

Optiscan strives for ‘live biopsies’ for head and neck cancers LTR Pharma wins ethics clearance for fresh erectile dysfunction trial Noxopharm’s quest to cure lupus inches a step further Optiscan (ASX:OIL) will launch an imaging study of...

ASX burns through 118 points or 1.36% Energy only sector in green after crude oil gains Broad retreat after three straight weeks of losses   ASX falls three weeks in a row It was a day of bloodletting on the ASX 200 today, plummeting 118...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Poor Chinese relations, Covid, war and US tariffs prove too much for device maker Uscom The Mayne Health takeover deal isn’t over, but the prognosis is dire Bioxyne strikes medical cannabis vape import deal   Uscom bows out Uscom (ASX:UCM...

Highlights Key Australian companies witnessed notable market attention this week. Resource, retail, and healthcare sectors emerged in focus across the ASX stock market. Broader ASX 200 sentiment reflects shifting investor in...

ASX closes at new high of 9094 points, up 0.7pc Broad momentum across sectors with 10 of 11 higher US-Australian critical mineral deals fuel more resource stock gains   ASX roars to new highs on US-Australia rare earths deal The ASX 200 s...

S&P/ASX 300 Index (ASX: XKO) healthcare share Immutep Ltd (ASX: IMM) is marching higher today. Shares in the clinical-stage biotech company closed on Friday trading for 30.5 cents. In morning trade on Monday, shares are changing hands f...

Highlights Duratec and Lovisa identified among undervalued Australian equities. Broader ASX landscape shows resilience amid market diversity. Infrastructure, retail, and technology sectors feature strong value cases. A...

Highlights Australian market steadies amid global shifts. Emerging undervalued companies gain investor attention. Technology and healthcare sectors lead potential recovery. Australian equities spotlight undervalued opp...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin A summary of the highlights from Broker Call Extra updates throughout the week past....

Highlights Australian tech sector shows resilience across biotechnology and software Key players such as (ASX:IMM), (ASX:NXL) and (ASX:TNE) driving sector momentum Focus on research, innovation, and global scalability shapin...

Biotechnology stocks can be high-risk but also high-reward. The key is latching on to one with a promising product pipeline and the ability to bring it to market. Wilsons Advisory's healthcare analysts believe Immutep Ltd (ASX: IMM) may...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

  Highlights Banks including (ASX:ANZ), (ASX:NAB) and (ASX:WBC) remained firm within the asx 200 Real estate majors such as (ASX:CHC), (ASX:SCG) and (ASX:SGP) advanced across sessions Uptrend and downtrend scans reflected c...

  Highlights Recent trading activity reflects increased appetite for high-risk equity positions Market sentiment appears aligned with speculative trends seen in previous cycles Volatility remains a concern as investor focus...

  Highlights Spotlight on selected small-cap movements from the ASX board Sectoral shifts driving attention toward lesser-known equities Strategic interest emerges around companies diversifying portfolios asx 200 comp...

 Audeara and Ear Science Institute Australia will strive to develop a more affordable bone-conduction hearing device Auditor voices “substantial doubt” over Universal Biosensors’ viability Freeze a jolly good fellow: Brent Owens take over...